甲磺酸阿帕替尼三线或三线以上治疗晚期胃腺癌的临床观察

Clinical observation of apatinib mesylate as third-line or above treatment for patients with advanced gastric adenocarcinoma

目的 探讨甲磺酸阿帕替尼三线或三线以上治疗晚期胃腺癌的临床疗效和安全性。方法 回顾性分析2014年12月至2016年1月接受过二线及二线以上化疗方案治疗失败的20例晚期胃腺癌患者，给阿帕替尼500 mg／天口服，持续用药至肿瘤进展或出现不可耐受的不良反应。结果 20例胃腺癌患者的有效率（RR）和疾病控制率（DCR）分别为10.0％和40.0％，中位无进展生存时间（PFS）和中位总生存时间（OS）分别为2.7个月和4.3个月。患者耐受性良好，常见的毒副反应为1～3级高血压、手足综合征和蛋白尿。结论 对于接受过二线及二线以上化疗方案治疗失败的晚期胃腺癌患者，阿帕替尼具有良好的疗效和安全性。

Objective To evaluate the efficacy and toxicity of apatinib mesylate as third-line or above treatment for patients with advanced gastric adenocarcinoma. Methods The clinical data of 20 patients with advanced gastric adenocarcinoma who failed at least two lines of prior chemotherapy from Dec 2014 to Jan 2016 were retrospectively analyzed. All patients received oral apatinib mesy- late 500 mg perday until disease progression or intolerable toxicity. Results The response rate （RR） and disease control rate （DCR） was 10. 0% and 40. 0%, respectively. The median progression free survival （PFS） and median overall survival （OS） were 2. 7 months and 4. 3 months, respectively. Apatinib treatment was well tolerated without severe toxicities; the common adverse events were grade 1 to 3 hypertension, hand-foot syndrome and proteinuria. Conclusion Apatinib mesylate is effective and tolerable for patients with ad- vanced gastric adenocarcinoma who failed second-line or obove chemotherapy.